Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Heart failure, NYHA class II or III
Last updated:
November 18, 2021
Status:
Concluded with an LOI
Manufacturer:
BGP Pharma ULC
Indication:
Metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung Cancer (NSCLC), platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, and glioblastoma
Last updated:
October 25, 2021
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Secondary Progressive Multiple Sclerosis (SPMS)
Last updated:
October 22, 2021
Tecentriq & Avastin (Atezolizumab & Bevacizumab)
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Unresectable or metastatic hepatocellular carcinoma (HCC) in adult patients who require systemic therapy
Last updated:
October 14, 2021
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA)
Last updated:
October 14, 2021
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible.
Last updated:
October 13, 2021
Zolgensma (onasemnogene abeparvovec)
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Spinal Muscular Atrophy
Last updated:
October 8, 2021
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Chronic Lymphocytic Leukemia (CLL) (previously untreated): With or without obinutuzumab, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) for whom a fludarabine-based regimen is inappropriate
Last updated:
October 5, 2021
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Chronic Lymphocytic Leukemia: As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Last updated:
October 5, 2021
Atectura Breezhaler (indacaterol /mometasone furoate)
Status:
Concluded with an LOI
Manufacturer:
Valeo Pharma Inc.
Indication:
Asthma
Last updated:
September 30, 2021